{"protocolSection": {"identificationModule": {"nctId": "NCT00820573", "orgStudyIdInfo": {"id": "35464"}, "organization": {"fullName": "The University of Texas Health Science Center at San Antonio", "class": "OTHER"}, "briefTitle": "Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM", "officialTitle": "Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2013-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-10"}, "primaryCompletionDateStruct": {"date": "2012-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-01-08", "studyFirstSubmitQcDate": "2009-01-09", "studyFirstPostDateStruct": {"date": "2009-01-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-11-05", "resultsFirstSubmitQcDate": "2013-12-11", "resultsFirstPostDateStruct": {"date": "2013-12-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-12-11", "lastUpdatePostDateStruct": {"date": "2013-12-13", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Eugenio Cersosimo", "investigatorTitle": "Associate Professor Medicine", "investigatorAffiliation": "The University of Texas Health Science Center at San Antonio"}, "leadSponsor": {"name": "The University of Texas Health Science Center at San Antonio", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "In patients with type 2 diabetes with inadequate glycemic control on diet and exercise after 6 weeks of treatment:\n\nObjective: To assess the effects of co-administration of sitagliptin and metformin compared to placebo on hepatic glucose production (HGP).\n\nHypothesis: After 6 weeks of treatment, the co-administration of sitagliptin and metformin provides greater reduction in hepatic glucose production (HGP) compared to placebo.", "detailedDescription": "PRIMARY:\n\nIn patients with type 2 diabetes with inadequate glycemic control on diet and exercise after 6 weeks of treatment:\n\nObjective: To assess the effects of co-administration of sitagliptin and metformin compared to placebo on hepatic glucose production (HGP).\n\nHypothesis: After 6 weeks of treatment, the co-administration of sitagliptin and metformin provides greater reduction in hepatic glucose production (HGP) compared to placebo.\n\nSECONDARY:\n\nIn patients with type 2 diabetes with inadequate glycemic control on diet and exercise after 6 weeks of treatment:\n\n1. Objective: To assess the effects of co-administration of sitagliptin and metformin compared to placebo on post-meal glucose during meal tolerance test (MTT).\n\n   Hypothesis: After 6 weeks of treatment the co-administration of sitagliptin and metformin provides greater reduction in the total glucose AUC (0-6 hr) during MTT compared to placebo.\n2. Objective: To assess the effects of co-administration of sitagliptin and metformin compared to placebo on fasting plasma glucose (FPG).\n\n   Hypothesis: After 6 weeks of treatment the co-administration of sitagliptin and metformin provides greater reduction in FPG compared to placebo.\n3. Objective: To assess the effects sitagliptin alone compared to placebo on HGP. Hypothesis: After 6 weeks of treatment, sitagliptin alone provides greater reduction in HGP compared to placebo\n\nEXPLORATORY OBJECTIVES:\n\n(i) Objective: after 6 weeks of treatment, to assess the effects co-administration of sitagliptin and metformin compared to placebo on:\n\n1. active and inactive incretin concentrations (fasting and post-meal GLP-1 and fasting and post-meal GIP).\n2. glucagon concentration (fasting and post-meal).\n3. parameters of insulin secretion and insulin sensitivity.\n4. splanchnic glucose uptake.\n\n   (ii) Objective: after 6 weeks of treatment, to assess the effects co-administration of sitagliptin and metformin compared to treatment with sitagliptin alone and metformin alone on:\n5. glucose concentration (fasting and total glucose AUC \\[0-6 hr\\]).\n6. active and inactive incretin concentrations (fasting and post-meal GLP-1 and fasting and post-meal GIP).\n7. glucagon concentration (fasting and post-meal).\n8. parameters of insulin secretion and insulin sensitivity.\n9. HGP.\n10. splanchnic glucose uptake. (iii) Objective: after 6 weeks of treatment, to assess the effects of sitagliptin alone and metformin alone compared to placebo on:\n11. glucose concentration (fasting and total glucose AUC \\[0-6 hr\\]).\n12. active and inactive incretin concentrations (fasting and post-meal GLP-1 and fasting and post-meal GIP).\n13. glucagon concentration (fasting and post-meal).\n14. parameters of insulin secretion and insulin sensitivity.\n15. HGP.\n16. splanchnic glucose uptake."}, "conditionsModule": {"conditions": ["Diabetes"], "keywords": ["Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 16, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo to be provided for 6 weeks", "interventionNames": ["Drug: Placebo"]}, {"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "Sitagliptin to be provided for 6 weeks", "interventionNames": ["Drug: Sitagliptin"]}, {"label": "Metformin", "type": "EXPERIMENTAL", "description": "Metformin to be provided for 6 weeks", "interventionNames": ["Drug: Metformin"]}, {"label": "Sitagliptin+Metfromin", "type": "EXPERIMENTAL", "description": "Sitagliptin + Metformin combined will be provided for 6 weeks", "interventionNames": ["Drug: Sitagliptin + Metformin"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin", "description": "tablet, 100 mg/day, 6 weeks", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia"]}, {"type": "DRUG", "name": "Metformin", "description": "tablet, 1000 mg/ bid, 6 weeks", "armGroupLabels": ["Metformin"], "otherNames": ["Glucophage"]}, {"type": "DRUG", "name": "Sitagliptin + Metformin", "description": "tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks", "armGroupLabels": ["Sitagliptin+Metfromin"], "otherNames": ["Januvia and glucophage"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo 6 weeks", "armGroupLabels": ["Placebo"], "otherNames": ["Placebo tablet"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Objective: Comparisons of the Effects of Co-administration of Sitagliptin and Metformin Alone or in Combination Versus Placebo on Baseline Endogenous Glucose Production (EGP).", "description": "Baseline endogenous glucose production prior to a mixed meal tolerance test (placebo) and following 6 weeks of either sitagliptin, metformin or sitagliptin plus metformin combination therapy in all 16 participants", "timeFrame": "6 weeks"}, {"measure": "Average of Plasma Glucose During Mixed Meal Tolerance Test (MTT) Compared to Baseline Plasma Glucose to Post Therapy (6-weeks).", "description": "The degree of suppression of baseline endogenous glucose production was measured in absolute values and as a percent of basal values at the end of each 6-week therapeutic period. The absolute values obtained in each sequence study group (both basal and post-meal) were compared amongst all groups.", "timeFrame": "6 weeks"}], "secondaryOutcomes": [{"measure": "Fasting Plasma Glucose 6 Weeks After Therapy", "description": "Basal pasma glucose was determined with the glucose oxidase method after each specific 6 week treatment. The absolute values obtained of basal plasma glucose at the end of each 6-week therapeutic period in each sequence study group (both basal and post-meal) were compared amongst all groups.", "timeFrame": "6 weeks"}, {"measure": "Changes in Plasma Glucose Post-MTT After Each Six Weeks of Therapy Compared to Baseline", "description": "The absolute values of mean plasma glucose post-meal (360 minutes)were determined after each specific 6 week treatment and these absolute values after each specific sequence therapy were compared amongst all groups.", "timeFrame": "360 min"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must meet all of the following inclusion criteria to participate in the study.\n* Patients with screening values/findings outside ranges described in the protocol may have one repeat determination performed and if the repeat value satisfies the criterion, they may continue in the screening process.\n* If the repeat value does not satisfy the criterion, the principal investigator will review the abnormal laboratory value and decide whether the subject may continue in the screening process.\n* All screening laboratory measurements are to be performed after an overnight fast \u226510 hours in duration.\n* Patients must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.\n* Patients can be either male or female.\n* Patients are \u226518 and \u226470 years of age on the day of signing informed consent.\n* Patients must meet the current American Diabetes Association criteria for the diagnosis of type 2 diabetes mellitus\n* Patients must be on diet or diet plus exercise therapy.\n* Patients must have a HbA1c \u2265 7.5% and \u2264 9.5%\n* Patients must have a BMI of 23-40 kg/m2\n* Patients must have the following laboratory values:\n\n  * Hematocrit Males \u2265 34 vol%\n  * Females \u2265 33vol%\n  * Serum creatinine \u2264 1.5 mg/dL in males and \u2264 1.4 mg/dL in females\n  * AST (SGOT): \u2264 2.5 times upper limit of normal\n  * ALT (SGPT): \u2264 2.5 times upper limit of normal\n  * Alkaline phosphatase \u2264 2.5 times upper limit of normal\n  * If serum creatinine is \\> 1.5 mg/dl in males and \\> 1.4 mg/dl in females, the Principal Investigator can include the patient if the measured GFR is \\>70 ml/min (24 hour creatinine clearance)\n* Patients must have been on a stable dose of allowed chronic medications for \u226530 days prior to entering the study.\n* Only patients whose body weight has been stable (\u00b14 pounds) over the three months prior to the study will be included.\n\nExclusion Criteria:\n\n* Patients are excluded from participation in the study if they meet any of the following criteria:\n\n  * Patient has type 1 diabetes.\n  * Patient has received insulin for more than one week within the previous year prior to entry.\n  * Patient has been treated with exenatide or a non-TZD, oral antihyperglycemic agent within the last 2 months or with a TZD (pioglitazone or rosiglitazone) within the last 4 months.\n  * Patient is receiving any medications with known adverse effects on glucose tolerance (e.g., systemic glucocorticoids, psychotropic drugs like clozapine, olanzapine, haloperidol, risperidone). Note: Patients may be taking stable doses of estrogens, other hormonal replacement therapy, or lipid and blood pressure lowering agents if the patient has been on these agents for the prior three months.\n  * Patient has evidence of a significant cardiovascular disorder within 6 months of signing informed consent (e.g. acute coronary syndrome, coronary artery intervention, stroke or transient ischemic neurological disorder) or has New York Heart Association Classification greater than Class 2; or has significant findings on ECG (other than non-specific ST-T wave changes); or peripheral vascular disease (history of claudication); or has dyspnea on exertion of one flight or less, or abnormal breath sounds on auscultation.\n  * Patient has a history of intolerance or hypersensitivity to a DPP-4 inhibitor or to metformin.\n  * Patient is pregnant or plans to become pregnant within the projected duration of the study.", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Eugenio Cersosimo, MD", "affiliation": "University of TX Health Science Center", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Texas Diabetes Institute", "city": "San Antonio", "state": "Texas", "zip": "78207", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}]}, "referencesModule": {"references": [{"pmid": "23579178", "type": "DERIVED", "citation": "Solis-Herrera C, Triplitt C, Garduno-Garcia Jde J, Adams J, DeFronzo RA, Cersosimo E. Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. Diabetes Care. 2013 Sep;36(9):2756-62. doi: 10.2337/dc12-2072. Epub 2013 Apr 11."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A 4 week washout period for those subjects on oral anti-diabetic therapy with sulfonylureas was used in 7 subjects", "recruitmentDetails": "Texas Diabetes Institute from March 2010 July 2011", "groups": [{"id": "FG000", "title": "Placebo,Sitagliptin,Metformin and Sitagliptin Plus Metformin", "description": "Sequence as described, starting placebo therapy for 6 weeks,followed by sitagliptin 100 mg once daily, then metformin 1000 mg twice daily for 6 weeks and the combination sitagliptn plus metformin for the final 6 weeks"}, {"id": "FG001", "title": "Sitagliptin, Metformin, Sitagliptin Plus Metformin, Placebo", "description": "Sequence as described, starting with sitagliptin 100 mg once daily, then metformin 1000 mg twice daily for 6 weeks, combination sitagliptn plus metformin for 6 weeks and then placebo therapy for the final 6 weeks"}, {"id": "FG002", "title": "Metformin, Sitagliptin Plus Metformin, Sitagliptin,Placebo", "description": "Sequence as described, starting with metformin 1000 mg twice daily for 6 weeks, combination sitagliptn plus metformin for 6 weeks, then sitagliptin 100 mg daily followed by placebo therapy for the final 6 weeks"}, {"id": "FG003", "title": "Sitagliptin Plus Metformin, Sitagliptin, Placebo,Metformin", "description": "Sequence as described, starting with combination sitagliptn plus metformin for 6 weeks, then sitagliptin 100 mg daily placebo therapy for 6 weeks and finally metforminfor 6 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "all subjects after 6 weeks of placebo therapy"}, {"id": "BG001", "title": "Metformin", "description": "all subjects after receiving 6 weeks of metformin therapy"}, {"id": "BG002", "title": "Sitagliptin", "description": "all subjects after receiving 6 weeks of sitagliptin therapy"}, {"id": "BG003", "title": "Metformin Plus Sitagliptin", "description": "all subjects after receiving 6 weeks of combined sitagliptin plus metformin therpay"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "16"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "16"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "6"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "2"}, {"groupId": "BG004", "value": "10"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "16"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Objective: Comparisons of the Effects of Co-administration of Sitagliptin and Metformin Alone or in Combination Versus Placebo on Baseline Endogenous Glucose Production (EGP).", "description": "Baseline endogenous glucose production prior to a mixed meal tolerance test (placebo) and following 6 weeks of either sitagliptin, metformin or sitagliptin plus metformin combination therapy in all 16 participants", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/kg.min", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "All participants received placebo, metformin, sitagliptin and the combination therapy for 6 weeks in random order"}, {"id": "OG001", "title": "Metformin", "description": "All participants received placebo, metformin, sitagliptin and the combination therapy for 6 weeks in random order"}, {"id": "OG002", "title": "Sitagliptin", "description": "All participants received placebo, metformin, sitagliptin and the combination therapy for 6 weeks in random order"}, {"id": "OG003", "title": "Sitagliptin Plus Metformin", "description": "All participants received placebo, metformin, sitagliptin and the combination therapy for 6 weeks in random order"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "0.2"}, {"groupId": "OG001", "value": "1.8", "spread": "0.2"}, {"groupId": "OG002", "value": "1.7", "spread": "0.2"}, {"groupId": "OG003", "value": "1.5", "spread": "0.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003"], "groupDescription": "A general unstructured variance-covariance matrix (ANOVA) was applied for measurements at different periods. Between-group comparisons after 6 wks of treatment were assessed using the ANOVA model at alpha=0.05 (two-sided).\n\n16 subjects provide \\~90% power to detect difference in EGP of 0.28 mg/kg.min (95% CI = 0.17 mg/kg.min).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.05", "statisticalMethod": "ANOVA"}]}, {"type": "SECONDARY", "title": "Fasting Plasma Glucose 6 Weeks After Therapy", "description": "Basal pasma glucose was determined with the glucose oxidase method after each specific 6 week treatment. The absolute values obtained of basal plasma glucose at the end of each 6-week therapeutic period in each sequence study group (both basal and post-meal) were compared amongst all groups.", "populationDescription": "All 16 participants were analyzed using ANOVA to compare results after each 6 week period of exposure to therapeutic agent(s)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dl", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "All participants received 6 weeks continuous therapy in random order of the following: placebo, metformin, sitagliptin and the combination sitagliptin plus metformin."}, {"id": "OG001", "title": "Metformin", "description": "All participants received 6 weeks continuous therapy in random order of the following: placebo, metformin, sitagliptin and the combination sitagliptin plus metformin"}, {"id": "OG002", "title": "Sitagliptin", "description": "All participants received 6 weeks continuous therapy in random order of the following: placebo, metformin, sitagliptin and the combination sitagliptin plus metformin"}, {"id": "OG003", "title": "Sitagliptin Plus Metformin", "description": "All participants received 6 weeks continuous therapy in random order of the following: placebo, metformin, sitagliptin and the combination sitagliptin plus metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "160", "spread": "4"}, {"groupId": "OG001", "value": "145", "spread": "5"}, {"groupId": "OG002", "value": "150", "spread": "4"}, {"groupId": "OG003", "value": "120", "spread": "6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003"], "groupDescription": "multivariate analysis was performed to compare results amongst all four groups", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.05", "statisticalMethod": "ANOVA", "ciPctValue": "95"}]}, {"type": "PRIMARY", "title": "Average of Plasma Glucose During Mixed Meal Tolerance Test (MTT) Compared to Baseline Plasma Glucose to Post Therapy (6-weeks).", "description": "The degree of suppression of baseline endogenous glucose production was measured in absolute values and as a percent of basal values at the end of each 6-week therapeutic period. The absolute values obtained in each sequence study group (both basal and post-meal) were compared amongst all groups.", "populationDescription": "power calculations with data from previous similar studies", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/kg.min", "timeFrame": "6 weeks", "groups": [{"id": "OG000", "title": "Placebo", "description": "Sitagliptin\n\nSitagliptin : tablet, 100 mg/day, 6 weeks"}, {"id": "OG001", "title": "Metformin", "description": "Metformin\n\nMetformin : tablet, 1000 mg/ bid, 6 weeks"}, {"id": "OG002", "title": "Sitagliptin", "description": "Sitagliptin + Metformin\n\nSitagliptin and Metformin : tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks"}, {"id": "OG003", "title": "Sitagliptin + Metformin", "description": "placebo for 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "spread": "0.2"}, {"groupId": "OG001", "value": "1.6", "spread": "0.2"}, {"groupId": "OG002", "value": "1.7", "spread": "0.2"}, {"groupId": "OG003", "value": "1.5", "spread": "0.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003"], "groupDescription": "ANOVA", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.05", "statisticalMethod": "ANOVA"}]}, {"type": "SECONDARY", "title": "Changes in Plasma Glucose Post-MTT After Each Six Weeks of Therapy Compared to Baseline", "description": "The absolute values of mean plasma glucose post-meal (360 minutes)were determined after each specific 6 week treatment and these absolute values after each specific sequence therapy were compared amongst all groups.", "populationDescription": "power calculation based on previous data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dl", "timeFrame": "360 min", "groups": [{"id": "OG000", "title": "Placebo", "description": "Sitagliptin\n\nSitagliptin : tablet, 100 mg/day, 6 weeks"}, {"id": "OG001", "title": "Metformin", "description": "Metformin\n\nMetformin : tablet, 1000 mg/ bid, 6 weeks"}, {"id": "OG002", "title": "Sitagliptin", "description": "Sitagliptin + Metformin\n\nSitagliptin and Metformin : tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks"}, {"id": "OG003", "title": "Sitagliptin+Metformin", "description": "placebo for 6 weeks"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "16"}, {"groupId": "OG003", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "205", "spread": "5"}, {"groupId": "OG001", "value": "191", "spread": "4"}, {"groupId": "OG002", "value": "195", "spread": "4"}, {"groupId": "OG003", "value": "161", "spread": "3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001", "OG002", "OG003"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.05", "statisticalMethod": "ANOVA"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "March 2010 to July 2011", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "all subjects after 6 weeks of placebo therapy", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 0, "otherNumAtRisk": 16}, {"id": "EG001", "title": "Metformin", "description": "all subjects after receiving 6 weeks of metformin therapy", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 0, "otherNumAtRisk": 16}, {"id": "EG002", "title": "Sitagliptin", "description": "all subjects after receiving 6 weeks of sitagliptin therapy", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 0, "otherNumAtRisk": 16}, {"id": "EG003", "title": "Metformin Plus Sitagliptin", "description": "all subjects after receiving 6 weeks of combined sitagliptin plus metformin therpay", "seriousNumAffected": 0, "seriousNumAtRisk": 16, "otherNumAffected": 0, "otherNumAtRisk": 16}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Eugenio Cersosimo, MD PhD", "organization": "University of Texas HSC at San Antonio", "email": "Eugenio.cersosimo@uhs-sa.com", "phone": "210 358 7200"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}